Table 1 Sociodemographic and clinical characteristics data (n= 280)
From: Factors affecting survival and prognosis in extensive stage small cell lung cancer
Variables | N | % |
|---|---|---|
Age | ||
Mean ± SD | 59.7 ± 9.3 | |
Median (min-max) | 60.0 (35–83) | |
< 65 | 191 | 68.2 |
≥ 65 | 89 | 31.8 |
Gender | ||
Female | 58 | 20.7 |
Male | 222 | 79.3 |
Tumor localization | ||
Right | 164 | 58.6 |
Left | 116 | 41.4 |
Brain metastasis | ||
No | 223 | 79.6 |
Yes | 57 | 20.4 |
Pleura metastasis | ||
No | 215 | 76.8 |
Yes | 65 | 23.2 |
Contralateral lung metastasis | ||
No | 211 | 75.4 |
Yes | 69 | 24.6 |
Liver metastasis | ||
No | 194 | 69.3 |
Yes | 86 | 30.7 |
Surrenal metastasis | ||
No | 205 | 73.2 |
Yes | 75 | 26.8 |
Bone metastasis | ||
No | 126 | 45.0 |
Yes | 154 | 55.0 |
Pancreas metastasis | ||
No | 274 | 97.9 |
Yes | 6 | 2.1 |
Extrathoracic lymph node metastasis | ||
No | 219 | 78.2 |
Yes | 61 | 21.8 |
1. Line treatment | ||
Cisplatin+etoposide | 222 | 79.3 |
Carboplatin+etoposide | 33 | 11.8 |
Oral etoposide | 10 | 3.6 |
Carboplatin+etoposide+atezolizumab | 15 | 5.3 |
Response to first-line treatment | ||
CR | 52 | 18.6 |
PR | 132 | 47.1 |
SD | 37 | 13.2 |
PD | 59 | 21.1 |
2. Line treatment | ||
Topotecan | 37 | 31.9 |
Cisplatin+irinotecan | 15 | 12.9 |
Cisplatin+etoposide | 14 | 12.1 |
CAV | 10 | 8.6 |
Other | 40 | 34.5 |
Number of cycles in the first line | ||
≤ 4 | 125 | 44.6 |
> 4 | 155 | 55.4 |
Thoracic residual radiotherapy | ||
No | 186 | 66.4 |
Yes | 94 | 33.6 |
PCI | ||
No | 213 | 76.1 |
Yes | 67 | 23.9 |
Progression after the first line | ||
No | 20 | 3.9 |
Yes | 260 | 96.1 |
Mortality | ||
Alive | 11 | 3.9 |
Exitus | 269 | 96.1 |
Follow-up time (months) | ||
Mean ± SD | 15.4 ± 19.8 | |
Median (min-max) | 11.0 (1–182) | |